Next Article in Journal
DNA Microarray‐Based Screening and Characterization of Traditional Chinese Medicine
Previous Article in Journal
Acknowledgement to Reviewers of Microarrays in 2016
Previous Article in Special Issue
The Potentials and Pitfalls of Microarrays in Neglected Tropical Diseases: A Focus on Human Filarial Infections
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessReview

Microarray Technology Applied to Human Allergic Disease

Division of Allergy and Clinical Immunology, Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Academic Editor: Phillip Stafford
Microarrays 2017, 6(1), 3;
Received: 16 November 2016 / Revised: 12 January 2017 / Accepted: 19 January 2017 / Published: 28 January 2017
(This article belongs to the Special Issue Microarrays in Immunology Research)
PDF [539 KB, uploaded 6 February 2017]


IgE antibodies serve as the gatekeeper for the release of mediators from sensitized (IgE positive) mast cells and basophils following a relevant allergen exposure which can lead to an immediate-type hypersensitivity (allergic) reaction. Purified recombinant and native allergens were combined in the 1990s with state of the art chip technology to establish the first microarray-based IgE antibody assay. Triplicate spots to over 100 allergenic molecules are immobilized on an amine-activated glass slide to form a single panel multi-allergosorbent assay. Human antibodies, typically of the IgE and IgG isotypes, specific for one or many allergens bind to their respective allergen(s) on the chip. Following removal of unbound serum proteins, bound IgE antibody is detected with a fluorophore-labeled anti-human IgE reagent. The fluorescent profile from the completed slide provides a sensitization profile of an allergic patient which can identify IgE antibodies that bind to structurally similar (cross-reactive) allergen families versus molecules that are unique to a single allergen specificity. Despite its ability to rapidly analyze many IgE antibody specificities in a single simple assay format, the chip-based microarray remains less analytically sensitive and quantitative than its singleplex assay counterpart (ImmunoCAP, Immulite). Microgram per mL quantities of allergen-specific IgG antibody can also complete with nanogram per mL quantities of specific IgE for limited allergen binding sites on the chip. Microarray assays, while not used in clinical immunology laboratories for routine patient IgE antibody testing, will remain an excellent research tool for defining sensitization profiles of populations in epidemiological studies. View Full-Text
Keywords: IgE; human; immunoenzymetric assay; immunosorbent allergen chip; ISAC; serodiagnosis; microarray; molecular allergen; allergen extract; component resolved diagnosis IgE; human; immunoenzymetric assay; immunosorbent allergen chip; ISAC; serodiagnosis; microarray; molecular allergen; allergen extract; component resolved diagnosis

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hamilton, R.G. Microarray Technology Applied to Human Allergic Disease. Microarrays 2017, 6, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics



[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top